SCHEMBL14317877

SCHEMBL14317877

Cc1ccc(N(Cc2ccncc2)C(=O)c2sc3ccccc3c2Cl)c(C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 3/20 0.49
▸ POLB P06746 1/20 0.49
▸ NLRP1 Q9C000 1/20 0.49
▸ CD274 Q9NZQ7 1/20 0.47
▸ SMN1; SMN2 Q16637 6/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ LMNA P02545 1/20 0.47
▸ NPC1 O15118 4/20 0.45
▸ RAB9A P51151 4/20 0.45
▸ MAPT P10636 3/20 0.45
▸ HPGD P15428 1/20 0.44
▸ DYRK1A Q13627 1/20 0.44
▸ PTPN7 P35236 1/20 0.43
▸ PTPN12 Q05209 1/20 0.43
▸ PTPN22 Q9Y2R2 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ F10 P00742 2/20 0.42
▸ CYP2D6 P10635 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14317872 0.90 DYRK1A (0.56) NPSR1POLBNLRP1CD274SMN1; SMN2
SCHEMBL14246970 0.90 HPGD (0.55) NPSR1POLBNLRP1CD274SMN1; SMN2
SCHEMBL14317880 0.90 SMN1; SMN2 (0.48) NPSR1POLBNLRP1CD274SMN1; SMN2
SCHEMBL14246842 0.85 NPSR1 (0.49) NPSR1POLBNLRP1CD274SMN1; SMN2
SCHEMBL14246865 0.84 DYRK1A (0.56) NPSR1POLBNLRP1CD274SMN1; SMN2
SCHEMBL14246812 0.83 NPSR1 (0.50) NPSR1POLBNLRP1CD274SMN1; SMN2
SCHEMBL14315169 0.81 NPSR1 (0.53) NPSR1POLBNLRP1CD274SMN1; SMN2
SCHEMBL14317875 0.80 LMNA (0.51) NPSR1POLBSMN1; SMN2LMNAMAPT
SCHEMBL14246841 0.79 NPSR1 (0.46) NPSR1POLBNLRP1CD274SMN1; SMN2
SCHEMBL14246746 0.79 CD274 (0.54) NPSR1POLBNLRP1CD274SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 — — US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 — — US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 — — US disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 NPSR1 1435/4885POLB 3840/4885NLRP1 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback